Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 17/20 | 1.00 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TACR3 | P29371 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21546075 | 1.00 | RIPK1 (1.00) | RIPK1PARP1TACR3 | |
| SCHEMBL20166107 | 0.89 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL25799180 | 0.89 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL30682162 | 0.89 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL29390142 | 0.89 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL20166101 | 0.89 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL20166312 | 0.87 | RIPK1 (1.00) | RIPK1TACR3 | |
| SCHEMBL20166311 | 0.87 | RIPK1 (1.00) | RIPK1TACR3 | |
| SCHEMBL20166510 | 0.86 | RIPK1 (0.75) | RIPK1PARP1TACR3 | |
| SCHEMBL20166514 | 0.86 | RIPK1 (0.75) | RIPK1PARP1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062735-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-27 | — | — | US | disclosed |
| US-20190345138-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| US-20190345138-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| WO-2018092089-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345138-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | RIPK1 440/4885PARP1 999/4885TACR3 2029/4885 |
| US-20200062735-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | RIPK1, RIPK4, RIPK3 | RIPK1 1/4885PARP1 154/4885TACR3 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.